|
 The company's shares rose 13 percent to $3.25 in after-market
trading on Tuesday.
The drug, emricasan, showed a statistically significant reduction in
the protein fragment, caspase-cleaved cytokeratin 18 (cCK18), when
compared with a placebo, in the overall patient population,
according to the three-month data.
Patients with advanced liver disease and cirrhosis usually have
higher levels of cCK18.
Conatus said the drug showed consistent improvement across
additional liver disease biomarkers in the overall patient
population.
The company said it expects to report six-month data from patients
who continued the treatment in the second quarter.
The six-month data will also allow the company to determine if the
mid-stage trial could qualify as a late-stage study, Conatus said.
[to top of second column] |
Emricasan is being tested for multiple liver indications.
Up to Tuesday's close of $2.87, Conatus shares had declined 71
percent in the past 12 months.
(Reporting by Shailesh Kuber; Editing by Sriraj Kalluvila)
[© 2016 Thomson Reuters. All rights
reserved.] Copyright 2016 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed. |
